TA-1 (ATCC® HB-10206)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma:lymphoblast B lymphocyte; somatic cell hybri  / 

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma:lymphoblast B lymphocyte; somatic cell hybri
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Strain

Strain: BALB/c (B cell); BALB/c (myeloma)

Applications
Animals were immunized with a transfected NIH 3T3 cell line, 18-3-7 that expresses full length normal human neu protein.
Storage Conditions liquid nitrogen vapor phase
Images
Derivation
Animals were immunized with a transfected NIH 3T3 cell line, 18-3-7 that expresses full length normal human neu protein. Spleen cells were fused with SP2/O myeloma cells (ATCC CRL 1581). The antibody recognizes substantially purified p100, human neu related protein, the full-length HER-2/neu molecule in tumor tissue (p185) or the extracellular domain (ECD) (p105) in serum, plasma, cell cultures and fluids. The TA-1 (HB-10206) and NB-3 (HB-10205) antibodies recognize two distinct epitopes on the human neu gene product [U.S. Pat. 5,401,638].
Comments
Animals were immunized with a transfected NIH 3T3 cell line, 18-3-7 that expresses full length normal human neu protein. Spleen cells were fused with SP2/O myeloma cells (ATCC CRL 1581). The antibody recognizes substantially purified p100, human neu related protein, the full-length HER-2/neu molecule in tumor tissue (p185) or the extracellular domain (ECD) (p105) in serum, plasma, cell cultures and fluids. The TA-1 (HB-10206) and NB-3 (HB-10205) antibodies recognize two distinct epitopes on the human neu gene product [U.S. Pat. 5,401,638].
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 105 viable cells/mL. Maintain cultures at a cell concentration between 1 X 105 and 1 X 106 cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium supplemented with an additional 10% fetal bovine serum and 7.5% DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype mouse IgG1 kappa
Name of Depositor WP Carney
References

Bacus SS, et al. Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol. Carcinog. 3: 350-362, 1990. PubMed: 1980588

Carney WP, McKenzie SJ. Detection and quantification of neu related proteins in the biological fluids of humans. US Patent 5,401,638 dated Mar 28 1995

Carney WP, et al. Detection of neu p185 in cell lysates. US Patent 5,604,107 dated Feb 18 1997

Rodrquez GC, et al. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am. J. Obstet. Gynecol. 168: 228-232, 1993. PubMed: 8420332

McKenzie SJ, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 4: 543-548, 1989. PubMed: 2566965

Singleton TP, et al. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum. Pathol. 23: 1141-1150, 1992. PubMed: 1356909

Animals were immunized with NIH/3T3 cells expressing full-length human HER-2/neu protein.

Basic Documentation
Other Documentation
References

Bacus SS, et al. Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol. Carcinog. 3: 350-362, 1990. PubMed: 1980588

Carney WP, McKenzie SJ. Detection and quantification of neu related proteins in the biological fluids of humans. US Patent 5,401,638 dated Mar 28 1995

Carney WP, et al. Detection of neu p185 in cell lysates. US Patent 5,604,107 dated Feb 18 1997

Rodrquez GC, et al. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am. J. Obstet. Gynecol. 168: 228-232, 1993. PubMed: 8420332

McKenzie SJ, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 4: 543-548, 1989. PubMed: 2566965

Singleton TP, et al. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum. Pathol. 23: 1141-1150, 1992. PubMed: 1356909

Animals were immunized with NIH/3T3 cells expressing full-length human HER-2/neu protein.